Metabolism of compound A by renal cysteine-S-conjugate β-lyase is not the mechanism of compound A-induced renal injury in the rat

Anesthesia and Analgesia

Volumn 82, Issue 4, 1996, Pages 770-774

  Martin, J L ^a,e   Laster, M J ^c   Kandel, L ^c   Kerschmann, R L ^d   Reed, G F ^b   Eger II, E I ^c  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIVICIN; AMINOOXYACETIC ACID; ANESTHETIC AGENT; BARA LIME; BUTHIONINE SULFOXIMINE; CALCIUM OXIDE; COMPOUND A; CYSTEINE CONJUGATE BETA LYASE; DRUG METABOLITE; ETHER DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; OXYGEN; SEVOFLURANE; SODIUM CARBONATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DRUG DEGRADATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; HALOGENATION; INHALATION ANESTHESIA; INHALATIONAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY NECROSIS; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINOOXYACETIC ACID; ANESTHETICS, INHALATION; ANIMALS; BUTHIONINE SULFOXIMINE; CARBON-SULFUR LYASES; ENZYME INHIBITORS; ETHERS; GLUTATHIONE; HYDROCARBONS, FLUORINATED; ISOXAZOLES; KIDNEY; KIDNEY DISEASES; LYASES; MALE; METHIONINE SULFOXIMINE; METHYL ETHERS; RATS; RATS, WISTAR;

EID: 0029916396     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199604000-00017     Document Type: Article

References (25)

1. Wallin R, Regan B, Napoli M, Stern I. Sevoflurane: a new inhalational anesthetic agent. Anesth Analg 1975;4:758-65.
2. Morio M, Fujii K, Satoh N, et al. Reaction of sevoflurane and its degradation products with soda lime. Toxicity of the byproducts. Anesthesiology 1992;77:1155-64.
3. Gonsowski C, Laster M, Eger EI, et al. Toxicity of compound A in rats. Effect of a 3-hour administration. Anesthesiology 1994; 80:556-65.
4. Gonsowski C, Laster M, Eger EI II, et al. Toxicity of compound A in rats. Effect of increasing duration of administration. Anesthesiology 1994;80:566-73.
5. 2 absorbents during low-flow anesthesia in surgical patients. Anesthesiology 1992;77:1064-9.
6. Bito H, Ikeda K. Long-duration, low-flow sevoflurane anesthesia using two carbon dioxide absorbents. Quantitation of deg-radation products in the circuit. Anesthesiology 1994;81:340-5.
7. Bito H, Ikeda K. Plasma inorganic fluoride and intracircuit degradation product concentrations in long-duration, low-flow sevoflurane anesthesia. Anesth Analg 1994;79:946-51.
8. Green T, Odum J. Structure/activity studies of the nephrotoxic and mutagenic action of cysteine conjugates of chloro- and fluoroalkenes. Chem Biol Interact 1985;4:15-31.
9. Potter C, Gandolfi A, Nagle R, Clayton J. Effects of inhaled chlorotrifluoroethylene and hexafluoropropene on the rat kidney. Toxicol Appl Pharmacol 1981;59:431-40.
10. Odum J, Green T. The metabolism and nephrotoxicity of tetra-chloroethylene in the rat. Toxicol Appl Pharmacol 1984;76: 306-18.
11. Dekant W, Anders M, Monks T. Bioactivation of halogenated xenobiotics by S-conjugate formation. In: Anders MW, Dekant W, Henschler D, et al., eds. Renal disposition and nephrotoxicity of xenobiotics. New York: Academic Press, 1993:187-215.
12. Dekant W, Vamvaks S, Anders M. Bioactivation of nephrotoxic haloalkenes by glutathione conjugation: formation of toxic and mutagenic intermediates by cysteine conjugate β-lyase. Drug Metab Rev 1989;20:43-83.
13. Lash L, Nelson RM, Van Dyke RA, Anders MW. Purification and characterization of human kidney cytosolic conjugate β-lyase activity. Drug Metab Dispos 1990;18:50-4.
14. Martin J, Kandel L, Laster M, et al. Studies of the mechanism of the nephrotoxicity of Compound A in rats. J Anesth In press, 1995.
15. Clayton JW. Toxicology of fluoroalkenes: review and research needs. Environ Health Perspec 1977;21:255-67.
16. Berndt WO, Mehendale HM. Effects of hexachlorobutadiene (HCBD) on renal function and renal organic ion transport in the rat. Toxicology 1979;14:55-65.
17. Cohen EN, Trudell JR, Edmunds HN, Watson E. Urinary metabolites of halothane in man. Anesthesiology 1976;43:392-401.
18. Finkelstein MB, Baggs RB, Anders MW. Nephrotoxicity of the glutathione and cysteine conjugates of 2-bromo,-2-chloro-1,1-difluoroethane. J Pharm Exp Ther 1992;261:148-52.
19. Elfarra AA, Jacobson I, Anders MW. Mechanism of S-(1,2-dichlorovinyl)glutathione-induced nephrotoxicity. Biochem Pharmacol 1986;35:283-8.
20. Lau SS, Jones TW, Huighet RJ, et al. Differences in the localization and extent of the renal proximal tubular necrosis caused by mercapturic acid and glutathione conjugates of 1,4-naphthoquinone and menidione. Toxicol Appl Pharmacol 1990;104:334-50.
21. Drew R, Miners JO. The effects of buthionine sulphoximine (BSO) on glutathione depletion and xenobiotic biotransformation. Biochem Pharmacol 1984;33:2989-94.
22. Lind RC, Gandolfi AJ, Hall PM. Glutathione depletion enhances subanesthetic halothane hepatotoxicity in guinea pigs. Anesthesiology 1992;77:721-7.
23. Jin L, Bailic TA, Davis MR, Kharasch ED. Nephrotoxicity of sevoflurane compound A [(fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether] in rats: evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate β-lyase. Biochem Biophys Res Commun 1995;210: 498-506.
24. Fang Z, Eger EI II. Effect of inflow rate on the concentration of Compound A resulting from the degradation of sevoflurane by soda lime and Baralyme® in a standard anesthetic circuit. Anesth Analg 1995;81:564-8.
25. Higuchi H, Sumikura H, Sumita S, et al. Renal function in patients with high serum fluoride concentrations after prolonged sevoflurane anesthesia. Anesthesiology 1995;83:449-58.